ImmunoVaccine Technologies selected as Canada's Top 10(TM) Life Sciences Companies



    HALIFAX, Sept. 30 /CNW/ - September 29, 2008 - ImmunoVaccine
Technologies (IVT), a vaccine development company, has been selected as one of
the winners of Canada's Top 10 Life Sciences Companies
(www.topcanadiancompanies.ca). Winners are chosen by an independent expert
panel of Canadian and U.S. venture capitalists. This award gives IVT the
opportunity to present at the 12th Annual Ottawa Venture and Technology Summit
on October 8, 2008 (www.ottawavts.com).
    "We have a technology that gives impressive results when applied to
therapeutic cancer and infectious disease vaccines and, as Canada's
Top 10 (TM), we now have an exclusive opportunity to present to top tier
venture capitalists," said Dr. Randal Chase, president & CEO of IVT.
    Canada's Top 10(TM) is organized by OCRI (Ottawa Centre for Research and
Innovation). Originally developed to promote the 10 most promising life
science companies from across Canada to Canadian and international investors
and partners, the competition now showcases Canada's life sciences, cleantech
and technology sectors. Of the 30 winning companies, only IVT has been chosen
from Atlantic Canada.
    Working in partnership with Canadian Consulates in Boston, New York City,
San Diego and San Francisco, winning companies will participate in targeted
investment forums in each city, providing them with an opportunity to meet
with Venture Capital investors who have expressed an active interest in
financing these companies. Since its inception in 1999, competition alumni
have secured more than $522M in venture capital financing.

    About IVT

    ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine
development company. Through its own biotech research, patented VacciMax(R)
and DepoVax(TM) technologies, and collaborations with partners, IVT creates
vaccines with the potential to help save and improve lives around the world.
    In January 2008, IVT licensed its technology to Pfizer Animal health,
marking a pivotal step in achieving its vision of delivering breakthrough
vaccines. www.immunovaccine.com




For further information:

For further information: Brian Lowe, Vice President, IVT, (902)
492-1819, bl.ivt@immunovaccine.com; Jennifer Ayotte, Communications, (902)
209-4704, jayotte@impactcommunications.ca

Organization Profile

IMMUNOVACCINE TECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890